Recombination polypeptide serving as group A streptococcic tetravalent vaccine protective antigen

A technology for recombinant polypeptides and vaccines, applied in the field of DNA recombination technology and methods in the Ming Dynasty, can solve problems such as autoimmune reactions
CN101845084BActive Publication Date: 2012-10-10WUHAN INST OF BIOLOGICAL PROD CO LTD
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
WUHAN INST OF BIOLOGICAL PROD CO LTD
Publication Date
2012-10-10

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides recombination polypeptide, which is prepared by gene recombination technology. The recombination polypeptide is prepared by splicing type-specific amino acid sequences of M1, M3, M6 and M18 serological-type M proteins of rheumatic fever immunogenic group A streptococcus prevailing in the Guangdong province of China, and a common section of conservative amino acid sequence of the C ends of the four serological-type M proteins, wherein the N ends of the four serological-type M proteins comprise protective antigen epitopes and do not comprise human cross reaction epitopes.The recombination polypeptide is experimentally proved to be capable of inducing the generation of bactericidins for the type specificity of the M1, M3 and M6 proteins of the A-group streptococcus soas to be used for preparing recombination polypeptide vaccines for the A-group streptococcus.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to the field of DNA recombination technology and vaccine medicine, more specifically, the present invention relates to a recombinant polypeptide, which can be used as four serotypes mainly targeting the four serotypes of group A streptococcus prevalent in Guangdong Province, my country, which can cause rheumatic fever. The protective antigen of the valent vaccine, the DNA sequence encoding the recombinant polypeptide, the vector containing the DNA sequence, the host cell containing the vector, the method for preparing the recombinant polypeptide by DNA recombinant technology, and the recombinant polypeptide in the development of group A streptococcal vaccine in the application. Background technique

[0002] Group A Streptococcus is one of the most common pathogenic Gram-positive bacteria in clinical practice. Group A streptococci can cause a variety of infectious diseases through air droplets, skin contact, etc. Among all ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More